+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Thyroid Gland Disorders: Diagnostics and Treatment Market- Product Image
Thyroid Gland Disorders: Diagnostics and Treatment Market- Product Image
New

Thyroid Gland Disorders: Diagnostics and Treatment Market

  • PDF Icon

    Report

  • 175 Pages
  • May 2025
  • Region: Global
  • BCC Research
  • ID: 6093582
Description Jump to:
The report analyzes trends in the global market for diagnostics and treatment of thyroid gland disorders. The report includes global revenue ($ million) for the base year 2024, estimated data for 2025, and for the forecast period of 2026 through 2030. The market is segmented by type of disease, product type, end user and region. The disease types are segmented into hypothyroidism, hyperthyroidism, thyroid cancer, and others. Product types are diagnostics and treatments. The diagnostics market is segmented into diagnostic, blood and imaging tests. The treatment market is segmented into medication, thyroid surgery, thyroid eye disease (TED) treatment and other end users are hospitals, specialty clinics, retail and online pharmacies, research and academic institutions, and patient and home care settings. The regions covered are North America, Europe, Asia-Pacific, and the Rest of the World (RoW. North American consists of the U.S., Canada, and Mexico. Europe includes Germany, the U.K., Italy, France, Spain and the Rest of Europe. Asia-Pacific includes China, Japan, India, South Korea and the Rest of Asia-Pacific.
This report focuses on trends and challenges that affect the market, including emerging technologies. It includes an analysis of the competitive landscape, with the rankings and market shares of the leading companies in the global market. The report has a chapter on environmental, social, and corporate governance (ESG) developments and includes company profiles that covers key financials, product portfolios and recent news.

Report Includes

  • 97 data tables and 62 additional tables
  • An overview of the current and future global markets for thyroid gland disorder
  • An analysis of the global market trends with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the size and revenue prospects of the global market, along with a market share analysis by type, disease type, end-user industry, and region
  • Facts and figures pertaining to market dynamics, technological advances, regulations, and the impact of macroeconomic factors
  • Analysis of market opportunities from a Porter’s Five Forces perspective, and a value chain analysis considering the prevailing micro- and macro environmental factors
  • Coverage of advances in thyroid cancer diagnosis such as genomic tests and treatments, as well as the side effects of current treatments such as radioactive iodine
  • Evaluation of ESG practices in the industry, consumer attitudes towards sustainability, risks and opportunity assessment, ratings and matrices
  • A patent analysis with emphasis on emerging technologies and new developments in the market
  • Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Company profiles of major players within the industry, including Amgen Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, Bristol-Myers Squibb Co., and Pfizer Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
Chapter 2 Market Overview
  • Overview
  • Conventional and Novel Technologies
  • Diagnostics in Thyroid Gland Disorders
  • Treatment of Thyroid Gland Disorders
  • Porter’s Five Forces Analysis
  • Potential for New Entrants (Moderate)
  • Bargaining Power of Suppliers (Moderate to High)
  • Bargaining Power of Buyers (Moderate to High)
  • Threat of Substitutes (Low to Moderate)
  • Industry Competitiveness (High)
  • Macroeconomic Factors
  • Aging Population
  • Regulatory Environment
  • Growing Incidence of Cancer
  • Government Policy and Collaboration
Chapter 3 Market Dynamics
  • Market Drivers
  • Growing Prevalence of Thyroid Cancer
  • Growing Prevalence of Thyroid Disorders
  • Rising Awareness and Policy Initiatives for Thyroid Disorders
  • Managing Thyroid Disorders through Personalized Medicine
  • Market Restraints
  • Side Effects of Treatment
  • Limited Access in Low-Income Regions
  • Market Opportunities
  • Incorporation of AI
  • Advanced Therapeutics
  • Market Challenges
  • Healthcare Disparities and Funding Challenges
  • Requirement for Lifelong Medication
Chapter 4 Regulatory Landscape
  • U.S. Approval Process
  • EU Approval Process
  • Asia-Pacific Approval Process
  • Drug Approval and Regulations
  • Levothyroxine-Based Treatments
  • Anti-Thyroid Medications
  • Biologic and Biosimilar Regulations
  • Medical Devices and Diagnostics Regulations
  • Point-of-Care and Laboratory Tests
  • Wearable and Digital Health Solutions
  • Future Trends and Regulatory Changes
Chapter 5 Emerging Technologies and Developments
  • Overview
  • Emerging Technologies in Thyroid Disorder Diagnostics
  • Hybrid Feature Selection and Deep Learning Framework
  • Autofluorescence Technology for Thyroid and Parathyroid Surgery
  • Regenerative Medicine and Bioengineering
  • Biowearable Technology
  • Mobile Apps
  • Recent Approvals and Launches of Drug and Device Products
  • Patent Analysis
  • Findings
Chapter 6 Market Segmentation Analysis
  • Segmentation Breakdown
  • Key Takeaways
  • Market Analysis by Disease Type
  • Hypothyroidism
  • Hyperthyroidism
  • Thyroid Cancer
  • Other Diseases
  • Market Analysis by Type
  • Takeaways
  • Diagnostics
  • Treatment
  • Market Analysis by End User
  • Takeaways
  • Treatment in Hospitals and Specialty Clinics
  • Retail and Online Pharmacies
  • Research and Academic Institutes
  • Home Care Settings
  • Geographic Breakdown
  • Market Analysis by Region
  • Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa
Chapter 7 Competitive Intelligence
  • Takeaways
  • Market Shares of Leading Companies
  • Developments and Strategies
  • Agreements, Collaborations and Partnerships
  • Acquisitions
Chapter 8 Sustainability in the Diagnostics and Treatment of Thyroid Gland Disorders Industry: ESG Perspective
  • Introduction to ESG
  • Initiatives by Leading Companies
  • ESG Risk Ratings
  • Research Viewpoint
Chapter 9 Appendix
  • Research Methodology
  • Sources
  • Abbreviations
  • Company Profiles
  • ABBOTT
  • ABBVIE INC.
  • AMGEN INC.
  • ASTRAZENECA
  • BRISTOL-MYERS SQUIBB CO.
  • F. HOFFMANN-LA ROCHE LTD.
  • FRESENIUS SE & CO. KGAA
  • GSK PLC.
  • LILLY
  • MERCK KGAA
  • NOVARTIS AG
  • PFIZER INC.
  • SANOFI
  • SIEMENS HEALTHINEERS AG
  • TERUMO CORP.
  • Emerging Start-ups/ Market Disruptors
List of Tables
Summary Table: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 1: Incidence of Thyroid Cancer in 2022
Table 2: Hypothyroidism Prevalence in the U.S. based on Optum Administrative Claims Database, 2012-2019
Table 3: Guidelines on Diagnosis and Management of Genetic Disorders of Thyroid Hormone, European Thyroid Association, 2024
Table 4: Comparative of HFSDLF Framework and Other Approaches, 2025
Table 5: Published Patents on Thyroid Gland Disorders: Diagnostics and Treatment, January 2024-January 2025
Table 6: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 7: Global Market for Diagnostics and Treatment of Hypothyroidism, by Region, Through 2030
Table 8: Global Market for Diagnostics and Treatment of Hyperthyroidism, by Region, Through 2030
Table 9: FDA-Approved Drugs in Advanced RR-DTC, 2025
Table 10: Tyrosine Kinase Inhibitors Tested in Thyroid Cancers, 2025
Table 11: Global Market for Diagnostics and Treatment of Thyroid Cancer, by Region, Through 2030
Table 12: Global Market for Diagnostics and Treatment of Other Thyroid Gland Disorders, by Region, Through 2030
Table 13: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 14: Global Market for Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
Table 15: Global Market for Diagnostics of Thyroid Gland Disorders, by Type, Through 2030
Table 16: Global Market for Blood Test Diagnostics of Thyroid Gland Disorders, by Region, Through 2030
Table 17: Global Market for Imaging Diagnostic Tests of Thyroid Gland Disorders, by Region, Through 2030
Table 18: Global Market for Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 19: Global Market for Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 20: Global Market for Medication Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 21: Global Market for Thyroid Surgery, by Region, Through 2030
Table 22: Biologics in the Pipeline for Potential Use in the Treatment of TED, 2025
Table 23: Global Market for the Treatment of TED, by Region, Through 2030
Table 24: Global Market for RAI Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 25: Global Market for Other Treatments of Thyroid Gland Disorders, by Region, Through 2030
Table 26: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 27: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Hospitals and Specialty Clinics, by Region, Through 2030
Table 28: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Retail and Online Pharmacies, by Region, Through 2030
Table 29: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Research and Academic Institutes, by Region, Through 2030
Table 30: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders in Home Care Settings, by Region, Through 2030
Table 31: Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, Through 2030
Table 32: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 33: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 34: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 35: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 36: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 37: North American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 38: U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 39: U.S. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 40: Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 41: Canadian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 42: Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 43: Mexican Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 44: Demographic Patterns in Thyroid Medication Use per 10,000 Population in European Countries, 2022
Table 45: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 46: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 47: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 48: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 49: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 50: European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 51: U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 52: U.K. Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 53: French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 54: French Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 55: Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 56: Italian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 57: German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 58: German Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 59: Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 60: Spanish Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 61: Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 62: Rest of European Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 63: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorder, by Disease, Through 2030
Table 64: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 65: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 66: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 67: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 68: Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, Through 2030
Table 69: Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease Type, Through 2030
Table 70: Chinese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 71: Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 72: Indian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 73: Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 74: Japanese Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 75: Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 76: Australian Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 77: South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 78: South Korean Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 79: Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 80: Rest of Asia-Pacific Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 81: South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 82: South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 83: South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 84: South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 85: South American Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 86: MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, Through 2030
Table 87: MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, Through 2030
Table 88: MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Diagnostics, Through 2030
Table 89: MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Treatment, Through 2030
Table 90: MEA Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, Through 2030
Table 91: Leading Companies in the Market, 2024
Table 92: Agreements, Collaborations and Partnerships in the Diagnostics and Treatment of Thyroid Gland Disorder Industry, 2021-2025
Table 93: Acquisitions in the Diagnostics and Treatment for Thyroid Gland Disorder Industry, 2023-2024
Table 94: ESG Highlights, by Leading Companies, 2023 and 2024
Table 95: ESG Risk Rankings, 2024
Table 96: Report Information Sources
Table 97: Abbreviations Used in this Report
Table 98: Abbott: Company Snapshot
Table 99: Abbott: Financial Performance, FY 2023 and 2024
Table 100: Abbott: Product Portfolio
Table 101: Abbott: News/Key Developments 2023-2025
Table 102: AbbVie Inc.: Company Snapshot
Table 103: AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 104: AbbVie Inc.: Product Portfolio
Table 105: AbbVie Inc.: News/Key Developments, 2023 and 2024
Table 106: Amgen Inc.: Company Snapshot
Table 107: Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 108: Amgen Inc.: Product Portfolio
Table 109: Amgen Inc.: News/Key Developments, 2021-2024
Table 110: AstraZeneca: Company Snapshot
Table 111: AstraZeneca: Financial Performance, FY 2023 and 2024
Table 112: AstraZeneca: Product Portfolio
Table 113: AstraZeneca: News/Key Developments, 2021-2024
Table 114: Bristol-Myers Squibb Co.: Company Snapshot
Table 115: Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 116: Bristol-Myers Squibb Co.: Product Portfolio
Table 117: Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 118: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 119: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 120: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 121: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 122: Fresenius SE & Co. KGaA: Company Snapshot
Table 123: Fresenius SE & Co. KGaA: Financial Performance, FY 2023 and 2024
Table 124: Fresenius SE & Co. KGaA: Product Portfolio
Table 125: Fresenius SE & Co. KGaA: News/Key Developments, 2023 and 2024
Table 126: GSK plc.: Company Snapshot
Table 127: GSK plc.: Financial Performance, FY 2023 and 2024
Table 128: GSK plc.: Product Portfolio
Table 129: GSK plc.: News/Key Developments, 2021-2024
Table 130: Lilly: Company Snapshot
Table 131: Lilly: Financial Performance, FY 2023 and 2024
Table 132: Lilly: Product Portfolio
Table 133: Lilly: News/Key Developments, 2023 and 2024
Table 134: Merck KGaA.: Company Snapshot
Table 135: Merck KGaA.: Financial Performance, FY 2023 and 2024
Table 136: Merck KGaA: Product Portfolio
Table 137: Merck KGaA.: News/Key Developments, 2021-2023
Table 138: Novartis AG: Company Snapshot
Table 139: Novartis AG: Financial Performance, FY 2023 and 2024
Table 140: Novartis AG: Product Portfolio
Table 141: Novartis AG: News/Key Developments, 2022-2024
Table 142: Pfizer Inc.: Company Snapshot
Table 143: Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 144: Pfizer Inc.: Product Portfolio
Table 145: Pfizer Inc.: News/Key Developments, 2022-2024
Table 146: Sanofi: Company Snapshot
Table 147: Sanofi: Financial Performance, FY 2023 and 2024
Table 148: Sanofi: Product Portfolio
Table 149: Sanofi: News/Key Developments, 2022 and 2023
Table 150: Siemens Healthineers AG: Company Snapshot
Table 151: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 152: Siemens Healthineers AG: Product Portfolio
Table 153: Siemens Healthineers AG: News/Key Developments, 2024
Table 154: Terumo Corp.: Company Snapshot
Table 155: Terumo Corp.: Financial Performance, FY 2022 and 2023
Table 156: Terumo Corp.: Product Portfolio
Table 157: Terumo Corp.: News/Key Developments, 2023
Table 158: Emerging Startups
List of Figures
Summary Figure: Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
Figure 1: Existing and Emerging Technologies for the Treatment of Thyroid Disorders
Figure 2: Porter’s Five Forces Market Analysis
Figure 3: Market Dynamics of Thyroid Gland Disorders
Figure 4: Shares of Global Thyroid Cancer Mortality in Males, by Region, 2022
Figure 5: Thyroid Health Awareness in the Saudi Population: A Community Study
Figure 6: Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Disease, 2024
Figure 7: Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Type, 2024
Figure 8: Shares of Global Market for Diagnostics of Thyroid Gland Disorders, by Type, 2024
Figure 9: Shares of Global Market for Treatment of Thyroid Gland Disorders by Type, 2024
Figure 10: Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by End User, 2024
Figure 11: Shares of Global Market for Diagnostics and Treatment of Thyroid Gland Disorders, by Region, 2024
Figure 12: North American Market Shares for Diagnostics and Treatment of Thyroid Gland Disorder, by Country, 2024
Figure 13: European Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
Figure 14: Asia-Pacific Market Shares for Diagnostics and Treatment of Thyroid Gland Disorders, by Country, 2024
Figure 15: Shares for Companies in the Market for Diagnostics and Treatment of Thyroid Gland Disorders, 2024
Figure 16: Abbott: Revenue Share, by Business Unit, FY 2024
Figure 17: Abbott: Revenue Share, by Country/Region, FY 2024
Figure 18: AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
Figure 19: AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
Figure 20: Amgen Inc.: Revenue Share, by Drug, FY 2024
Figure 21: Amgen Inc.: Revenue Share, by Country/Region, FY 2024
Figure 22: AstraZeneca: Revenue Share, by Business Unit, FY 2024
Figure 23: AstraZeneca: Revenue Share, by Region/Country, FY 2024
Figure 24: Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
Figure 25: Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
Figure 26: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 27: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 28: Fresenius SE & Co. KGaA: Revenue Share, by Business Unit, FY 2024
Figure 29: Fresenius SE & Co. KGaA: Revenue Share, by Country/Region, FY 2024
Figure 30: GSK plc.: Revenue Share, by Business Unit, FY 2024
Figure 31: GSK plc.: Revenue Share, by Country/Region, FY 2024
Figure 32: Lilly: Revenue Share, by Business Unit, FY 2024
Figure 33: Lilly: Revenue Share, by Country/Region, FY 2024
Figure 34: Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 35: Merck KGaA.: Revenue Share, by Country/Region, FY 2024
Figure 36: Novartis AG: Revenue Share, by Business Unit, FY 2024
Figure 37: Novartis AG: Revenue Share, by Country/Region, FY 2024
Figure 38: Pfizer Inc.: Revenue Share, by Business Unit, FY 2024
Figure 39: Pfizer Inc.: Revenue Share, by Country/Region, FY 2024
Figure 40: Sanofi: Revenue Share, by Business Unit, FY 2024
Figure 41: Sanofi: Revenue Share, by Country/Region, FY 2024
Figure 42: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 43: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 44: Terumo Corp.: Revenue Share, by Business Unit, FY 2023
Figure 45: Terumo Corp.: Revenue Share, by Country/Region, FY 2023

Executive Summary

The global market for diagnostics and treatment of thyroid gland disorders was valued at $15.5 billion in 2024 and is estimated to increase from $16.3 billion in 2025 to reach $21.0 billion by 2030, at a compound annual growth rate (CAGR) of 5.2% from 2025 through 2030.

The pharmaceutical industry is increasingly focusing on targeted and personalized therapies. There is a shift from traditional synthetic drugs to therapeutic biologic medicines, which are more efficacious, have better patient outcomes, and improve quality of life. Diagnostics include blood tests (TSH, T3, T4), imaging (ultrasound, CT, MRI), and molecular testing for early detection. Treatments include hormone replacement therapy (levothyroxine), anti-thyroid drugs, radioactive iodine therapy, targeted biologics, and minimally invasive surgeries.

Current Market Scenario

Hypothyroidism, hyperthyroidism, thyroid cancer, and autoimmune thyroid diseases affect millions of people globally, with aging populations, lifestyle factors, and iodine deficiency driving their incidence. In North America, the incidence of hypothyroidism and thyroid cancer cases is rising, while in Asia-Pacific, especially India, faces increasing congenital hypothyroidism. Thyroid cancer is also on the rise, particularly among women in the U.S. and parts of Asia and South America. Thyroid cancer has become the fastest-growing cancer among women over the past three decades. However, disparities in thyroid disease care remain a challenge, influenced by societal and structural factors that impact access to
diagnosis and treatment.

Segmental Analysis

Hypothyroidism accounts for more than half of the market, followed by hyperthyroidism and thyroid cancer and conditions such as thyroid nodules, goiter, thyroiditis, and rare genetic disorders. The demand for synthetic levothyroxine in treating hypothyroidism, for Tepezza to treat thyroid eye disease (TED), and advanced technologies in thyroid surgery are driving the market.

By disease, hypothyroidism accounted for 51.8% of the market in 2024 due to the increasing prevalence of Hashimoto’s thyroiditis and congenital hypothyroidism. By type, treatment accounted for 63.5% of the market in 2024. By region, North America held the highest share (42.4%) in 2024 due to the presence of many leading companies and increased healthcare expenditures.

Companies Mentioned

  • Abbott
  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Se & Co. Kgaa
  • Gsk Plc.
  • Lilly
  • Merck Kgaa
  • Novartis Ag
  • Pfizer Inc.
  • Sanofi
  • Siemens Healthineers Ag
  • Terumo Corp.

Table Information

Report AttributeDetails
No. of Pages175
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 21 Billion
Compound Annual Growth Rate5.2%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Thyroid Gland Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Thyroid Gland Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 184 Pages
  • Global
From
Thyroid Gland Disorder Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Thyroid Gland Disorder Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 300 Pages
  • Global
From
Thyroid Gland Disorder Treatment - Global Strategic Business Report - Product Image

Thyroid Gland Disorder Treatment - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Thyroid Gland Disorder Treatment Market by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel: Global and Forecast up to 2027 - Product Image

Thyroid Gland Disorder Treatment Market by Disease Type, Drug Type, Route of Administration, and Distribution/Sales Channel: Global and Forecast up to 2027

  • Report
  • 223 Pages
  • Global
From
Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.